Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDaniele RamazzottiMRMarco Gabriele RaddiFPFederica Pilo

Discussion

Loading...

Member takes

Overview

Prospective analysis improved risk stratification and identified clonal evolution patterns in MDS, indicating potential for enhanced clinical management.

Key Points

  • Dynamic validation of IPSS-M showed improved predictive performance in 1,002 MDS patients over time, enhancing risk assessment.
  • Clonal evolution of mutations demonstrated significant prognostic implications, with CCF metrics indicating risk of AML progression.
  • Utilizing peripheral blood and bone marrow analysis, the study achieved a 97.1% concordance rate for mutation detection accuracy.
  • Longitudinal monitoring revealed key mutations like TP53 and RUNX1 that independently predict worsening clinical outcomes in MDS patients.

Cite This Study

Ramazzotti et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d82bhttps://doi.org/10.1182/blood-2025-3842
View Full Paper
Ask AI
Bookmark
Share